The Ω-3 fatty acid docosahexaenoic acid selectively induces apoptosis in tumor-derived cells and suppress tumor growth in gastric cancer

Ortega, Loréna; Lobos-González, Lorena; Reyna-Jeldes, Mauricio; Cerda, Daniela; Fuente-Ortega, Erwin de la; Castro, Patricio; Bernal, Giuliano; Coddou, Claudio

doi:10.1016/j.ejphar.2021.173910

Cited by 10 publications

(15 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EPnF meshes were charged with different compounds similar to Ω-3 fatty acid docosahexaenoic acid (DHA). These were recently described as selective inductors of apoptosis in tumor-derived cells and suppress tumor growth in gastric cancer [ 46 ]. Cisplatinum, or cis-diamminedichloroplatinum (II), is a well-known chemotherapeutic drug with different abbreviation names.…”

Section: Resultsmentioning

confidence: 99%

Electrospun Poly(acrylic acid-co-4-styrene sulfonate) as Potential Drug-Eluting Scaffolds for Targeted Chemotherapeutic Delivery Systems on Gastric (AGS) and Breast (MDA-Mb-231) Cancer Cell Lines

et al. 2022

Self Cite

View full text Add to dashboard Cite

Potential drug-eluting scaffolds of electrospun poly (acrylic acid-co-styrene sulfonate) P(AA-co-SS) in clonogenic assays using tumorigenic gastric and ovarian cancer cells were tested in vitro. Electrospun polymer nanofiber (EPnF) meshes of PAA and PSSNa homo- and P(AA-co-SS) copolymer composed of 30:70, 50:50, 70:30 acrylic acid (AA) and sodium 4-styrene sulfonate (SSNa) units were performed by electrospinning (ES). The synthesis, structural and morphological characterization of all EPnF meshes were analyzed by optical and electron microscopy (SEM-EDS), infrared spectroscopy (FTIR), contact angle, and X-ray diffraction (XRD) measurements. This study shows that different ratio of AA and SSNa of monomers in P(AA-co-SS) EPnF play a crucial role in clonogenic in vitro assays. We found that 50:50 P(AA-co-SS) EPnF mesh loaded with antineoplastic drugs can be an excellent suppressor of growth-independent anchored capacities in vitro assays and a good subcutaneous drug delivery system for chemotherapeutic medication in vivo model for surgical resection procedures in cancer research.

show abstract

Section: Resultsmentioning

confidence: 99%

Electrospun Poly(acrylic acid-co-4-styrene sulfonate) as Potential Drug-Eluting Scaffolds for Targeted Chemotherapeutic Delivery Systems on Gastric (AGS) and Breast (MDA-Mb-231) Cancer Cell Lines

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Smith et al confirmed that oral administration of fish oil (1.86 g/day EPA+1.5 g/day DHA) for 6 months delayed the loss of muscle mass and function, and prevented sarcopenia in healthy older adults without severe adverse events related to ω-3 PUFA 48. Preclinical studies have confirmed that ω-3 PUFAs can inhibit GC progress by inducing apoptosis of GC cells in various ways 19 20 49 50. In addition, a randomised controlled trial has shown that 2 g/day ω-3 PUFAs during neoadjuvant chemotherapy can improve the pathological response rate and the subsequent R0 resection rate 51.…”

Section: Discussionmentioning

confidence: 97%

“… 48 Preclinical studies have confirmed that ω-3 PUFAs can inhibit GC progress by inducing apoptosis of GC cells in various ways. 19 20 49 50 In addition, a randomised controlled trial has shown that 2 g/day ω-3 PUFAs during neoadjuvant chemotherapy can improve the pathological response rate and the subsequent R0 resection rate. 51 Moreover, ω-3 PUFAs also play a synergistic role with cisplatin to enhance its inhibitory effect on GC.…”

Section: Discussionmentioning

confidence: 99%

“…17 Furthermore, recent preclinical studies have shown that ω-3 PUFAs can also inhibit GC-related cell growth and metastasis. [18][19][20] However, to our knowledge, studies on DFS after oral immunonutritional supplement (INS) after surgery for advanced GC are lacking.…”

Section: Strengths and Limitations Of This Studymentioning

confidence: 99%

“…Ryan et al found that enteral nutrition enriched with 2.2 g of EPA/day can maintain skeletal muscle mass after esophagectomy 17. Furthermore, recent preclinical studies have shown that ω-3 PUFAs can also inhibit GC-related cell growth and metastasis 18–20. However, to our knowledge, studies on DFS after oral immunonutritional supplement (INS) after surgery for advanced GC are lacking.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effects of oral immunonutritional supplement on 3-year disease-free survival in gastric cancer patients with pathological stage III after total gastrectomy (CRUCIAL): study protocol of a multicentre, randomised clinical trial

et al. 2023

View full text Add to dashboard Cite

IntroductionThe nutritional status of patients with gastric cancer (GC) after total gastrectomy continues to deteriorate and lasts a long time after discharge, which is an independent risk factor for mortality. Recent guidelines have recommended appropriate nutritional support after discharge for cancer surgery patients with malnutrition or nutritional risk. The evidence on the efficacy of oral immunonutritional supplement (INS) and its effect on long-term disease-free survival (DFS) in patients with GC is limited. This study was designed to test the hypothesis that oral INS compared to diet alone may improve 3-year DFS of GC patients with pathological stage III after total gastrectomy (Nutrition Risk Screening 2002 score ≥3 at discharge).Methods and analysisThis is a pragmatic, open-label, multicentre, randomised controlled study. 696 eligible GC patients with pathological stage III after total gastrectomy will be randomised in a 1:1 ratio to oral INS group or normal diet group for 6 months. The primary endpoint is 3-year DFS after discharge. The following secondary endpoints will be evaluated: 3-year overall survival; unplanned readmission rate at 3 and 6 months after discharge; quality of life, body mass index and haematological index at 3, 6 and 12 months after discharge; incidence of sarcopenia at 6 and 12 months after discharge; and the tolerance to chemotherapy. The adverse events of oral INS will also be evaluated during the intervention.Ethics and disseminationThis study was approved by the ethics committee of Jinling Hospital, Nanjing University (number 2021NZKY-069-01). The present study may validate the effectiveness of oral immunonutritional therapy in improving 3-year DFS for GC patients with pathological stage III after total gastrectomy for the first time. The results of this trial will be disseminated in peer-reviewed journals and at scientific conferences.Trial registration numberNCT05253716.

show abstract

Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons

Modica,

La Salvia,

Liccardi

et al. 2024

Endocrine

View full text Add to dashboard Cite

Purpose Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies originating from cells with a neuroendocrine phenotype. The complex relationship between lipid metabolism and cancer is gaining interest and a potential anti-cancer effect of lipid lowering agents is being considered. This review aims to discuss the current understanding and treatment of dyslipidaemia in NENs, focusing on the role of lipid lowering agents, including new therapeutic approaches, and future perspectives as possible tool in cancer prevention and tumor-growth control. Methods We performed an electronic-based search using PubMed updated until December 2023, summarizing the available evidence both in basic and clinical research about lipid lowering agents in NENs. Results Dyslipidemia is an important aspect to be considered in NENs management, although randomized studies specifically addressing this topic are lacking, unlike other cancer types. Available data mainly regard statins, and in vitro studies have demonstrated direct antitumor effects, including antiproliferative effects in some cancers, supporting possible pleiotropic effects also in NENs, but data remain conflicting. Ezetimibe, omega 3-fatty acids, fibrates and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) may enhance the regulation of lipid homeostasis, as demonstrated in other cancers. Conclusions Targeting dyslipidemia in NENs should be part of the multidisciplinary management and an integrated approach may be the best option for both metabolic and tumor control. Whether lipid lowering agents may directly contribute to tumor control remains to be confirmed with specific studies, focusing on association with other metabolic risk, disease stage and primary site.

show abstract

The Ω-3 fatty acid docosahexaenoic acid selectively induces apoptosis in tumor-derived cells and suppress tumor growth in gastric cancer

Cited by 10 publications

References 57 publications

Electrospun Poly(acrylic acid-co-4-styrene sulfonate) as Potential Drug-Eluting Scaffolds for Targeted Chemotherapeutic Delivery Systems on Gastric (AGS) and Breast (MDA-Mb-231) Cancer Cell Lines

Electrospun Poly(acrylic acid-co-4-styrene sulfonate) as Potential Drug-Eluting Scaffolds for Targeted Chemotherapeutic Delivery Systems on Gastric (AGS) and Breast (MDA-Mb-231) Cancer Cell Lines

Effects of oral immunonutritional supplement on 3-year disease-free survival in gastric cancer patients with pathological stage III after total gastrectomy (CRUCIAL): study protocol of a multicentre, randomised clinical trial

Dyslipidemia, lipid-lowering agents and neuroendocrine neoplasms: new horizons

Contact Info

Product

Resources

About